Search company, investor...

Predict your next investment

Corporation
neuca.pl

About NEUCA

NEUCA is active in numerous areas of the national healthcare market. The company develops dynamically both in the pharmaceutical and medical field what results in numerous possibilities for the company and the employees.

Headquarters Location

Poland

Want to inform investors similar to NEUCA about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest NEUCA News

Neuca Clinical Trials Purchases 72.6% Stake in OncoBay

Jan 4, 2023

Increases its clinical operations in the U.S. by joining forces with the Florida-based CRO. 01.04.23 Neuca Clinical Trials Inc., a holding company held by Neuca Group, the proprietor of Clinscience international CRO , has increased its clinical operations in the U.S. by purchasing a 72.6% stake in OncoBay, a Tampa, Florida-based CRO founded by Moffit Cancer Center. OncoBay is a boutique CRO offering comprehensive, custom-curated solutions for biotechnology companies developing avant-garde immuno-oncology therapies. The company provides unrivaled scientific support and conducts clinical operations in the U.S. with a team of 100+ oncology experts. Leveraging Distinct Competencies The investment reflects the strong partner dynamic between Clinscience and OncoBay, already collaborating for over two years, leveraging their distinct competencies to bridge Europe and the U.S. Clinscience offers OncoBay its leading-edge global Data Management and Technology services and conducts clinical operations in Europe. In turn, OncoBay enables Clinscience to conduct clinical operations in the U.S. and grants access to the US biotechnology market. Currently, the companies are jointly advancing several dozen immuno-oncology projects. "The unbound dedication to immuno-oncology, tailored solutions, and use of Technology and Data consistency are elements that tied our organizations right from the beginning. Our combined powers, supercharged by complementing competencies, proprietary technologies and streamlined organizational structure, set the stage for a full-scale global alternative in the clinical research market. It allows us to further expand our abilities in cancer research providing our clients with comprehensive support in their pursuit to develop innovative cancer treatments," said Tomek Dabrowski, CEO at Clinscience, responsible for the clinical trials segment at NEUCA Group. "The connection between OncoBay and Clinscience provides an exciting opportunity to influence global oncology clinical research. The combination of oncology expertise, global footprint, and innovative analytics with in-line data assessment tools create the foundation for a unique organization that aims to accelerate research impacting cancer patients' lives. The larger connections to the world-class Patient Access available through the Clinscience European Partner Sites Program distinguish this partnership and our ability to transform clinical research positively," said Krystyna Kowalczyk, Oncobay CEO, and co-founder. Krystyna Kowalczyk, and Dannelle Palmer, OncoBay's chief operating officer, join the leadership team at NEUCA Group's clinical research segment. Kowalczyk takes the CEO role of the combined structures of Clinscience and OncoBay. Tomek Dabrowski continues his responsibilities as president and chairman of the Board. Trending

NEUCA Acquisitions

3 Acquisitions

NEUCA acquired 3 companies. Their latest acquisition was OncoBay Clinical on January 04, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/4/2023

$99M

Corporate Majority

2

7/8/2016

Subscribe to see more

$99M

Subscribe to see more

10

1/7/2016

Seed / Angel

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/4/2023

7/8/2016

1/7/2016

Investment Stage

Seed / Angel

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

Note

Corporate Majority

Subscribe to see more

Subscribe to see more

Sources

2

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.